Phytoestrogens in the prevention and treatment of postmenopausal osteoporosis: molecular mechanisms, therapeutic evidence, and traditional Chinese medicine applications

Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency-related uncoupling of bone remodeling, with progressive bone loss and fracture susceptibility. We conducted a structured narrative review using searches of PubMed/MEDLINE, Web of Science Core Collection, Scopus, and China National Knowledge Infrastructure from inception to 27 August 2026. We evaluated cell and animal studies, observational studies, randomized trials, and meta-analyses separately. Established phytoestrogen classes, principally isoflavones, lignans, and coumestans, were distinguished from stilbenes included in broader classification schemes, coumarin-related plant metabolites, other isolated metabolites, botanical extracts, and multi-ingredient traditional Chinese medicine (TCM) preparations. Experimental studies support selected metabolite-specific effects on estrogen receptor, bone-remodeling, inflammatory, and redox pathways. Evidence for other proposed pathways and microbiota-mediated effects remains scarce or model-dependent. Human studies are heterogeneous and often involve generally healthy, early postmenopausal, or osteopenic women rather than patients with established PMO who are at high fracture risk. A 2024 meta-analysis of 63 randomized controlled trials (9,026 participants) found modest gains versus placebo at the lumbar spine (mean difference: 0.0175 g/cm 2 ; 95% confidence interval: 0.0088–0.0263) and femoral neck (mean difference: 0.0172 g/cm 2 ; 95% confidence interval: 0.0046–0.0298). These changes in bone mineral density (BMD) are surrogate outcomes and do not establish antifracture efficacy. Evidence for TCM-related isolated metabolites, botanical extracts, and multi-ingredient preparations is predominantly preclinical or limited by incomplete product characterization. Defined phytoestrogen preparations may warrant further study as adjuncts, but current evidence does not support replacing approved osteoporosis treatments.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1879143
Primary Topic
Phytoestrogen effects and research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phytoestrogens in the prevention and treatment of postmenopausal osteoporosis: molecular mechanisms, therapeutic evidence, and traditional Chinese medicine applications

辛林伟, Mimi Niu, Youqiong Mo, Haihua Li et al.
1 links
Frontiers in Pharmacology
Phytoestrogen effects and research
article

Phytoestrogens in the prevention and treatment of postmenopausal osteoporosis: molecular mechanisms, therapeutic evidence, and traditional Chinese medicine applications

辛林伟, Mimi Niu, Youqiong Mo, Haihua Li, Jian Chen, Xu Han
article en

Abstract

Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency-related uncoupling of bone remodeling, with progressive bone loss and fracture susceptibility. We conducted a structured narrative review using searches of PubMed/MEDLINE, Web of Science Core Collection, Scopus, and China National Knowledge Infrastructure from inception to 27 August 2026. We evaluated cell and animal studies, observational studies, randomized trials, and meta-analyses separately. Established phytoestrogen classes, principally isoflavones, lignans, and coumestans, were distinguished from stilbenes included in broader classification schemes, coumarin-related plant metabolites, other isolated metabolites, botanical extracts, and multi-ingredient traditional Chinese medicine (TCM) preparations. Experimental studies support selected metabolite-specific effects on estrogen receptor, bone-remodeling, inflammatory, and redox pathways. Evidence for other proposed pathways and microbiota-mediated effects remains scarce or model-dependent. Human studies are heterogeneous and often involve generally healthy, early postmenopausal, or osteopenic women rather than patients with established PMO who are at high fracture risk. A 2024 meta-analysis of 63 randomized controlled trials (9,026 participants) found modest gains versus placebo at the lumbar spine (mean difference: 0.0175 g/cm 2 ; 95% confidence interval: 0.0088–0.0263) and femoral neck (mean difference: 0.0172 g/cm 2 ; 95% confidence interval: 0.0046–0.0298). These changes in bone mineral density (BMD) are surrogate outcomes and do not establish antifracture efficacy. Evidence for TCM-related isolated metabolites, botanical extracts, and multi-ingredient preparations is predominantly preclinical or limited by incomplete product characterization. Defined phytoestrogen preparations may warrant further study as adjuncts, but current evidence does not support replacing approved osteoporosis treatments.

Frontiers in PharmacologyVol. 17
Guilin Medical University (CN)
Good health and well-being
Phytoestrogen effects and research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon